Franklin Genomic Advancements Etf Volatility
| HELX Etf | USD 29.86 0.33 1.12% |
Franklin Genomic Adv secures Sharpe Ratio (or Efficiency) of -0.14, which denotes the etf had a -0.14% return per unit of standard deviation over the last 3 months. Franklin Genomic Advancements exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Franklin Genomic's Mean Deviation of 0.8706, coefficient of variation of (778.57), and Standard Deviation of 1.2 to check the risk estimate we provide. Key indicators related to Franklin Genomic's volatility include:
60 Days Market Risk | Chance Of Distress | 60 Days Economic Sensitivity |
Franklin Genomic Etf volatility depicts how high the prices fluctuate around the mean (or its average) price. In other words, it is a statistical measure of the distribution of Franklin daily returns, and it is calculated using variance and standard deviation. We also use Franklin's beta, its sensitivity to the market, as well as its odds of financial distress to provide a more practical estimation of Franklin Genomic volatility.
Franklin |
Franklin Genomic Adv Etf Volatility Analysis
Volatility refers to the frequency at which Franklin Genomic etf price increases or decreases within a specified period. These fluctuations usually indicate the level of risk that's associated with Franklin Genomic's price changes. Investors will then calculate the volatility of Franklin Genomic's etf to predict their future moves. A etf that has erratic price changes quickly hits new highs, and lows are considered highly volatile. A etf with relatively stable price changes has low volatility. A highly volatile etf is riskier, but the risk cuts both ways. Investing in highly volatile security can either be highly successful, or you may experience significant failure. There are two main types of Franklin Genomic's volatility:
Historical Volatility
This type of etf volatility measures Franklin Genomic's fluctuations based on previous trends. It's commonly used to predict Franklin Genomic's future behavior based on its past. However, it cannot conclusively determine the future direction of the etf.Implied Volatility
This type of volatility provides a positive outlook on future price fluctuations for Franklin Genomic's current market price. This means that the etf will return to its initially predicted market price. This type of volatility can be derived from derivative instruments written on Franklin Genomic's to be redeemed at a future date.Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Franklin Genomic Adv Average Price is the average of the sum of open, high, low and close daily prices of a bar. It can be used to smooth an indicator that normally takes just the closing price as input.
Franklin Genomic Projected Return Density Against Market
Given the investment horizon of 90 days the etf has the beta coefficient of 1.0003 . This usually indicates Franklin Genomic Advancements market returns are sensitive to returns on the market. As the market goes up or down, Franklin Genomic is expected to follow.Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Franklin Genomic or Franklin Templeton Investments sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Franklin Genomic's price will be affected by overall etf market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Franklin etf's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Franklin Genomic Advancements has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Predicted Return Density |
| Returns |
What Drives a Franklin Genomic Price Volatility?
Several factors can influence a etf's market volatility:Industry
Specific events can influence volatility within a particular industry. For instance, a significant weather upheaval in a crucial oil-production site may cause oil prices to increase in the oil sector. The direct result will be the rise in the stock price of oil distribution companies. Similarly, any government regulation in a specific industry could negatively influence stock prices due to increased regulations on compliance that may impact the company's future earnings and growth.Political and Economic environment
When governments make significant decisions regarding trade agreements, policies, and legislation regarding specific industries, they will influence stock prices. Everything from speeches to elections may influence investors, who can directly influence the stock prices in any particular industry. The prevailing economic situation also plays a significant role in stock prices. When the economy is doing well, investors will have a positive reaction and hence, better stock prices and vice versa.The Company's Performance
Sometimes volatility will only affect an individual company. For example, a revolutionary product launch or strong earnings report may attract many investors to purchase the company. This positive attention will raise the company's stock price. In contrast, product recalls and data breaches may negatively influence a company's stock prices.Franklin Genomic Etf Risk Measures
Given the investment horizon of 90 days the coefficient of variation of Franklin Genomic is -730.52. The daily returns are distributed with a variance of 1.44 and standard deviation of 1.2. The mean deviation of Franklin Genomic Advancements is currently at 0.87. For similar time horizon, the selected benchmark (Dow Jones Industrial) has volatility of 0.77
α | Alpha over Dow Jones | -0.28 | |
β | Beta against Dow Jones | 1.00 | |
σ | Overall volatility | 1.20 | |
Ir | Information ratio | -0.24 |
Franklin Genomic Etf Return Volatility
Franklin Genomic historical daily return volatility represents how much of Franklin Genomic etf's daily returns swing around its mean - it is a statistical measure of its dispersion of returns. The ETF inherits 1.199% risk (volatility on return distribution) over the 90 days horizon. By contrast, Dow Jones Industrial accepts 0.7626% volatility on return distribution over the 90 days horizon. Performance |
| Timeline |
About Franklin Genomic Volatility
Volatility is a rate at which the price of Franklin Genomic or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Franklin Genomic may increase or decrease. In other words, similar to Franklin's beta indicator, it measures the risk of Franklin Genomic and helps estimate the fluctuations that may happen in a short period of time. So if prices of Franklin Genomic fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility.
Please read more on our technical analysis page.Under normal market conditions, the fund invests at least 80 percent of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. Franklin Genomic is traded on BATS Exchange in the United States.
Franklin Genomic's stock volatility refers to the amount of uncertainty or risk involved with the size of changes in its stock's price. It is a statistical measure of the dispersion of returns on Franklin Etf over a specified period of time, often expressed as the standard deviation of daily returns. In other words, it measures how much Franklin Genomic's price varies over time.
3 ways to utilize Franklin Genomic's volatility to invest better
Higher Franklin Genomic's etf volatility means that the price of its stock is changing rapidly and unpredictably, while lower stock volatility indicates that the price of Franklin Genomic Adv etf is relatively stable. Investors and traders use stock volatility as an indicator of risk and potential reward, as stocks with higher volatility can offer the potential for more significant returns but also come with a greater risk of losses. Franklin Genomic Adv etf volatility can provide helpful information for making investment decisions in the following ways:- Measuring Risk: Volatility can be used as a measure of risk, which can help you determine the potential fluctuations in the value of Franklin Genomic Adv investment. A higher volatility means higher risk and potentially larger changes in value.
- Identifying Opportunities: High volatility in Franklin Genomic's etf can indicate that there is potential for significant price movements, either up or down, which could present investment opportunities.
- Diversification: Understanding how the volatility of Franklin Genomic's etf relates to your other investments can help you create a well-diversified portfolio of assets with varying levels of risk.
Franklin Genomic Investment Opportunity
Franklin Genomic Advancements has a volatility of 1.2 and is 1.58 times more volatile than Dow Jones Industrial. 10 percent of all equities and portfolios are less risky than Franklin Genomic. You can use Franklin Genomic Advancements to enhance the returns of your portfolios. The etf experiences a large bullish trend. Check odds of Franklin Genomic to be traded at $32.85 in 90 days.Poor diversification
The correlation between Franklin Genomic Advancements and DJI is 0.64 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Franklin Genomic Advancements and DJI in the same portfolio, assuming nothing else is changed.
Franklin Genomic Additional Risk Indicators
The analysis of Franklin Genomic's secondary risk indicators is one of the essential steps in making a buy or sell decision. The process involves identifying the amount of risk involved in Franklin Genomic's investment and either accepting that risk or mitigating it. Along with some common measures of Franklin Genomic etf's risk such as standard deviation, beta, or value at risk, we also provide a set of secondary indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 0.8706 | |||
| Coefficient Of Variation | (778.57) | |||
| Standard Deviation | 1.2 | |||
| Variance | 1.43 | |||
| Information Ratio | (0.24) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential etfs, we recommend comparing similar etfs with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Franklin Genomic Suggested Diversification Pairs
Pair trading is one of the very effective strategies used by professional day traders and hedge funds capitalizing on short-time and mid-term market inefficiencies. The approach is based on the fact that the ratio of prices of two correlating shares is long-term stable and oscillates around the average value. If the correlation ratio comes outside the common area, you can speculate with a high success rate that the ratio will return to the mean value and collect a profit.
The effect of pair diversification on risk is to reduce it, but we should note this doesn't apply to all risk types. When we trade pairs against Franklin Genomic as a counterpart, there is always some inherent risk that will never be diversified away no matter what. This volatility limits the effect of tactical diversification using pair trading. Franklin Genomic's systematic risk is the inherent uncertainty of the entire market, and therefore cannot be mitigated even by pair-trading it against the equity that is not highly correlated to it. On the other hand, Franklin Genomic's unsystematic risk describes the types of risk that we can protect against, at least to some degree, by selecting a matching pair that is not perfectly correlated to Franklin Genomic Advancements.
When determining whether Franklin Genomic Adv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Franklin Genomic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Franklin Genomic Advancements Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Franklin Genomic Advancements Etf: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Franklin Genomic Advancements. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
The market value of Franklin Genomic Adv is measured differently than its book value, which is the value of Franklin that is recorded on the company's balance sheet. Investors also form their own opinion of Franklin Genomic's value that differs from its market value or its book value, called intrinsic value, which is Franklin Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Franklin Genomic's market value can be influenced by many factors that don't directly affect Franklin Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Franklin Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Franklin Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Franklin Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.